1. ALLA AKTIER
  2. NYHETER
  3. XBRANE BIOPHARMA

Xbrane Biopharma

Nyheter Xbrane Biopharma Nyheter alla bolag

Xbrane publishes answers to questions received in recent days.

Following the communication regarding the delay in FDA approval for Lucamzi (Ximluci in the U.S.) and the Q3 report, Xbrane has received numerous questions. As many stakeholders have raised similar concerns, we have done our best to address these questions in the attached document.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

Attachments

Xbrane publishes answers to questions received in recent days.
Q&A Q3 2025 EN

Datum 2025-10-28, kl 21:00
Källa MFN
Bifogade filer
Xbrane publishes answers to questions received in recent days.
Q&A Q3 2025 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!